The nanomedicine refers to highly-specific medical
intervention at the molecular scale for treating the diseases or restructuring
the damaged tissues as it is an offshoot of nanotechnology. Moreover, the
nanomedicine utilizes nano-sized tools for the diagnosis, prevention and
treatment of disease, and to gain increased understanding of the complex
underlying pathophysiology of the disease. It includes three nanotechnology
areas of diagnosis, imaging agents and the drug delivery with the nanoparticles
in the 1-1,000nm range, polymer therapeutics and biochips. Furthermore,
nanomedicines are structured to maximize the benefit/risk ratio, and their
toxicity must be calculated not only by sufficiently long term in vitro and in
vivo studies, but also pass multiple clinical studies. The key players of this
market are making the huge investment in the related research and development
programs for dominating the huge market share across the globe which further
proved to be profitable for leading the fastest market growth during the
forecasted period.
According to the report analysis, ‘Global
Nanomedicine Market - Drivers, Opportunities, Trends And Forecasts: 2017-2023‘
it states that there are several key players which are recently functioning in
this market more significantly by adopting the profitable strategies and
policies for leading the highest market share includes Merck & Co. Inc, Hoffmann-La
Roche Ltd, Gilead Sciences, Novartis AG, Amgen Inc, Pfizer Inc, Eli Lilly and
Company, Sanofi, Nanobiotix SA, UCB SA and several others. Additionally, the
key players of this market are studying and analyzing the key strength of the
competitors and guidelines of the respective government for working across the
globe more smoothly which beneficial for attaining the highest market growth
during the forecasted period.
The popular of nanomedicines utilized now for enable
oral drug delivery and its requirement is increasing significantly. Although
these nano-vectors are structured to translocate among the gastrointestinal
tract, lung, and blood-brain barrier, the potential of drug transferred to the
organ is lower than 1%, therefore developments are challenging. For
instance, The Global Nanomedicine Market is expected to observe an effective CAGR
of 17.1% during the forecast period of 2017-2023.
Although, in 2016, the Oncology sector is the main
therapeutic area for nanomedicine application, which encompassed more than 35%
of the total market share. A main objective in this sector is anticipated to
drive the growth of the nanomedicine market in the future. Additionally, with
all this the market of nanomedicines is spread across the globe which majorly
includes Americas, Europe, Asia Pacific, and Rest of the World (ROW). However,
the Americas are set to be the prominent region for the nanomedicine market
growth followed by Europe. Furthermore,
the Asia Pacific region and ROW are set to be the most developing regions.
Japan is set to be the most attractive destination and in Africa, the popularity
and the usage of numerous nano-drugs are anticipated to rise during the
forecasted period. Therefore, in the near future it is anticipated that the
global market of nanomedicine will increase more significantly over the recent
few years.
To know more, click on the link below:-
Related
Report:
Contact
Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
No comments:
Post a Comment